# KCTD6

## Overview
KCTD6 is a gene that encodes the protein potassium channel tetramerization domain containing 6, which is a member of the KCTD family of proteins. This protein is characterized by the presence of a BTB/POZ domain, which is crucial for its role as a scaffolding or adaptor protein in the ubiquitin-proteasome system. KCTD6 primarily functions in the regulation of protein turnover, particularly in muscle cells, by acting as a substrate adaptor for the cullin-3 (Cul3) E3 ubiquitin ligase complex. It facilitates the degradation of specific proteins, such as the small ankyrin-1 isoform 5 (sAnk1.5), through ubiquitination processes. The protein forms homomeric complexes, typically as tetramers, and its interactions are modulated by post-translational modifications like acetylation. KCTD6 is expressed in various tissues, including the heart and skeletal muscle, and plays a significant role in muscle differentiation and function. Its involvement in protein turnover and cellular regulation underscores its potential significance in various clinical conditions, including hereditary spherocytosis and muscle-related disorders (Lange2012Obscurin).

## Structure
KCTD6 is a protein characterized by the presence of a BTB/POZ domain, which is crucial for its structural and functional properties. This domain facilitates the formation of homomeric complexes, primarily as dimers and tetramers, although it does not form pentamers like some other KCTD family members (Lange2012Obscurin). The N-terminal BTB/POZ domain is essential for initial dimer formation, while the C-terminus is important for complete tetramerization and interaction with other proteins (Lange2012Obscurin).

KCTD6 interacts with cullin-3 (Cul3), an E3 ligase, through its BTB domain, which binds Cul3 with a dissociation constant (Kd) of 2.2 nM, indicating a strong interaction (Ji2016Structural). The binding involves a conserved aromatic residue and a negatively charged patch in the binding pocket, with the v-loop in the BTB domain playing a significant role (Ji2016Structural). KCTD6 does not form heteromers with its closest paralogue KCTD21 or with KCTD5 (Lange2012Obscurin).

Post-translational modifications, such as acetylation, enhance the binding of KCTD6 to its interaction partner sAnk1.5, although this does not necessarily increase sAnk1.5 turnover (Lange2012Obscurin). The protein's structure and interactions suggest its role as a scaffolding/adaptor protein in the ubiquitin-proteasome system (Lange2012Obscurin).

## Function
KCTD6 is a protein involved in the regulation of protein turnover, particularly in muscle cells. It functions as a substrate adaptor for cullin-3, an E3 ubiquitin ligase, facilitating the degradation of specific proteins such as the small ankyrin-1 isoform 5 (sAnk1.5) through ubiquitination processes (Lange2012Obscurin). KCTD6 forms parallel homo-tetramers, with its N-terminal BTB/POZ domain crucial for dimer formation and its C-terminus important for tetramerization and protein interactions (Lange2012Obscurin). 

In muscle cells, KCTD6 interacts with sAnk1.5, and this interaction is enhanced by the acetylation of sAnk1.5, which promotes the assembly of a protein complex with cullin-3, thereby regulating protein turnover (Lange2012Obscurin). KCTD6 is expressed in various tissues, including the heart and skeletal muscle, and its expression is up-regulated during muscle development, indicating its role in muscle differentiation and function (Lange2012Obscurin). 

KCTD6 is also implicated in the spatial and temporal expression of proteins during muscle development, acting as a scaffolding or adaptor protein in complexes involving cullin-3 (Lange2012Obscurin). Its role in protein turnover is crucial for maintaining cellular function and muscle integrity.

## Clinical Significance
Mutations or alterations in the KCTD6 gene have been implicated in several clinical conditions. KCTD6 is involved in the regulation of protein turnover, particularly in muscle and erythrocyte cells, through its interaction with small ankyrin-1 (sAnk1.5) and cullin-3. Disruptions in these interactions can lead to altered protein stability and turnover, which may contribute to the development of hereditary spherocytosis, a condition characterized by deformed red blood cells. This condition is linked to mutations in ankyrin-1, particularly those affecting the KCTD6 binding site, which can impair the interaction between ankyrin-1 and KCTD6, affecting the erythrocyte membrane cytoskeleton (Lange2012Obscurin).

In muscle tissue, KCTD6 is involved in the turnover of sAnk1.5, and its altered expression or interaction can lead to muscle-related conditions. Patients with hereditary spherocytosis may also exhibit symptoms of skeletal muscle myopathy and/or cardiomyopathy, suggesting a potential common molecular malfunction involving ankyrin-1 and KCTD6/cullin-3 (Lange2012Obscurin). While specific neurological disorders are not detailed in the provided context, KCTD6's role in protein degradation and cellular signaling suggests that its dysfunction could potentially impact other cellular processes and conditions.

## Interactions
KCTD6 is known to interact with several proteins, primarily through its N-terminal BTB/POZ domain, which facilitates protein-protein interactions. It forms homomeric complexes, typically as tetramers, and acts as an adaptor for the cullin-3 (Cul3) ubiquitin ligase complex, playing a crucial role in protein ubiquitination and degradation (Lange2012Obscurin; Liu2013The). KCTD6 specifically interacts with small ankyrin-1 (sAnk1.5), regulating its protein turnover through the ubiquitin-proteasome system. This interaction is modulated by posttranslational modifications such as acetylation, which enhances the binding of KCTD6 to sAnk1.5 (Lange2012Obscurin).

KCTD6 also forms a complex with obscurin and Cul3, influencing the localization and degradation of sAnk1.5. In obscurin knockout models, the spatial organization of these proteins is altered, affecting their interaction and protein turnover (Lange2012Obscurin). Additionally, KCTD6 is involved in deubiquitination processes, interacting with ubiquitin-specific proteases like USP11, which suggests its role in modulating protein stability and cellular signaling pathways (Skoblov2013Protein). These interactions highlight the significance of KCTD6 in cellular regulation and its potential involvement in disease mechanisms.


## References


[1. (Ji2016Structural) Alan X. Ji, Anh Chu, Tine Kragh Nielsen, Samir Benlekbir, John L. Rubinstein, and Gilbert G. Privé. Structural insights into kctd protein assembly and cullin3 recognition. Journal of Molecular Biology, 428(1):92–107, January 2016. URL: http://dx.doi.org/10.1016/j.jmb.2015.08.019, doi:10.1016/j.jmb.2015.08.019. This article has 54 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2015.08.019)

[2. (Lange2012Obscurin) Stephan Lange, Sue Perera, Phildrich Teh, and Ju Chen. Obscurin and kctd6 regulate cullin-dependent small ankyrin-1 (sank1.5) protein turnover. Molecular Biology of the Cell, 23(13):2490–2504, July 2012. URL: http://dx.doi.org/10.1091/mbc.e12-01-0052, doi:10.1091/mbc.e12-01-0052. This article has 55 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1091/mbc.e12-01-0052)

[3. (Skoblov2013Protein) Mikhail Skoblov, Andrey Marakhonov, Ekaterina Marakasova, Anna Guskova, Vikas Chandhoke, Aybike Birerdinc, and Ancha Baranova. Protein partners of <scp>kctd</scp> proteins provide insights about their functional roles in cell differentiation and vertebrate development. BioEssays, 35(7):586–596, April 2013. URL: http://dx.doi.org/10.1002/bies.201300002, doi:10.1002/bies.201300002. This article has 72 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/bies.201300002)

[4. (Liu2013The) Zhepeng Liu, Yaqian Xiang, and Guihong Sun. The kctd family of proteins: structure, function, disease relevance. Cell &amp; Bioscience, November 2013. URL: http://dx.doi.org/10.1186/2045-3701-3-45, doi:10.1186/2045-3701-3-45. This article has 96 citations.](https://doi.org/10.1186/2045-3701-3-45)